Overview

Effect of Metformin and Rosiglitazone Over no Diabetic With Metabolic Syndrome Patients.

Status:
Completed
Trial end date:
2009-01-01
Target enrollment:
0
Participant gender:
All
Summary
To compare the effect of insulin sensitizing drugs (metformin and rosiglitazone) over glucose homeostasis (GH) in no diabetic metabolic syndrome individuals. A randomized blinded clinical trial did in patients with metabolic syndrome (n=30), without diabetes. Prior to detailed information and signature of informed consent by patients were done three treatment groups by randomized technique; a) Placebo, b) Metformin (850 mg/day), c) Rosiglitazone (4 mg/day), treatment was administered for 8 weeks. GH was measured before and after treatment using oral glucose tolerance test (OGTT), and IR-index (Homeostatic Model). Determination was performed on weight, size, body mass index, plicometry, blood pressure, fasting glucose levels, triglycerides, HDL-cholesterol and insulin.
Phase:
Phase 2/Phase 3
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
J JESUS VENEGAS, MD
Collaborators:
Instituto Mexicano del Seguro Social
National Council of Science and Technology, Mexico
Treatments:
Metformin
Rosiglitazone
Criteria
Inclusion Criteria:

- > 18 years old.

- Metabolic Syndrome criteria of World Health Organization .

Exclusion Criteria:

- Diabetes Mellitus

- Allergic to Metformin,

- Allergic to rosiglitazone.

- Hepatic disease.

- Hearth disease.